Peptides for Bone Density & Osteoporosis Prevention

Osteoporosis affects approximately 3.5 million people in the UK, causing over 500,000 fragility fractures annually. The condition is characterised by reduced bone mineral density and deterioration of bone microarchitecture, increasing fracture risk — particularly of the hip, spine, and wrist.

Several peptide-based treatments are already established in clinical practice for osteoporosis. Teriparatide (recombinant PTH 1-34) is NICE-approved as a bone-building treatment, and calcitonin has a long history of use for bone pain. Growth hormone and IGF-1 play crucial roles in bone metabolism, making GH secretagogues of research interest.

Bone is a dynamic tissue constantly undergoing remodelling — the balance between osteoblast bone formation and osteoclast bone resorption determines bone density. Osteoporosis develops when resorption exceeds formation, a process accelerated by oestrogen decline in menopause, ageing, vitamin D deficiency, and inactivity.

All information is educational. Osteoporosis assessment and treatment should follow NICE TA161/TA204 under GP or endocrinologist supervision. DEXA scanning is the gold-standard diagnostic tool.